Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

GILD has just started a ph3 NASH Cirrhosis trial for compensated patients , MELD score below 12. It might compete directly with Emricasan for LC compensated patients, with the difference that Emricasan is targeting high portal veni pressure patients, whereas GILD is using reduction in fibrosis stage as primary endpoint, ie I doubt they could prescribe it for patients who have high HPVG


Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) - Full Text View - ClinicalTrials.gov